Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model - Dakin, H; Rombach, I; Dritsaki, M; Gray, A; Ball, C; Lamb, SE; Nanchahal, J (Bone and Joint Open, 2022)